National Research Institute of Tuberculosis and Lung Disease (NRITLD) Protocol for the Treatment of Patients with COVID-19

被引：2

作者：

Mirenayat, Maryam Sadat ^{[1
]}

Abedini, Atefeh ^{[1
]}

Kiani, Arda ^{[2
]}

Eslaminejad, Alireza ^{[2
]}

Adiminaghan, Parisa ^{[3
]}

Malekmohammad, Majid ^{[2
]}

Heshmatnia, Jalal ^{[4
]}

Nadji, Seyed Alireza ^{[5
]}

Idani, Esmaeil ^{[1
]}

Zahiri, Reyhaneh ^{[1
]}

Lookzadeh, Somayeh ^{[1
]}

Sheikhzade, Hakimeh ^{[4
]}

Dastan, Farzaneh ^{[1
]}

Toutkaboni, Mihan Porabdollah ^{[1
]}

Rezaei, Mitra Sadat ^{[5
]}

Askari, Elham ^{[1
]}

Tabarsi, Payam ^{[4
]}

Marjani, Majid ^{[4
]}

Moniri, Afshin ^{[4
]}

Hashemian, Seyed Mohammad Reza ^{[4
]}

Farzanegan, Behrooz ^{[2
]}

Abtahian, Zahra ^{[4
]}

Yassari, Fatemeh ^{[1
]}

Mansouri, Nazanin ^{[1
]}

Mansouri, Davood ^{[4
]}

Vasheghani, Maryam ^{[1
]}

Mansourafshar, Babak ^{[4
]}

Dezfoli, Mojtaba Mokhber ^{[2
]}

Soleimani, Salman ^{[2
]}

Seifi, Sharareh ^{[1
]}

Naghashzadeh, Farah ^{[6
]}

Fakharian, Atefeh ^{[1
]}

Varahram, Mohammad ^{[7
]}

Jamaati, Hamidreza ^{[1
]}

Zali, Alireza ^{[8
]}

Velayati, Ali Akbar ^{[4
]}

机构：

[1] Shahid Beheshti Univ Med Sci, Natl Res Inst TB & Lung Dis NRITLD, Chron Resp Dis Res Ctr CRDRC, Tehran, Iran

[2] Shahid Beheshti Univ Med Sci, Natl Res Inst TB & Lung Dis, Tracheal Dis Res Ctr, Tehran, Iran

[3] Shahid Beheshti Univ Med Sci, NRITLD, Dept Pulm & Sleep Med, Tehran, Iran

[4] Shahid Beheshti Univ Med Sci, Natl Res Inst TB & Lung Dis, Clin TB & Epidemiol Res Ctr, Tehran, Iran

[5] Shahid Beheshti Univ Med Sci, Natl Res Inst TB & Lung Dis, Virol Res Ctr, Tehran, Iran

[6] Shahid Beheshti Univ Med Sci, Natl Res Inst TB & Lung Dis NRITLD, Lung Transplantat Res Ctr LTRC, Tehran, Iran

[7] Shahid Beheshti Univ Med Sci, Natl Res Inst TB & Lung Dis, Mycobacteriol Res Ctr, Tehran, Iran

[8] Shahid Beheshti Univ Med Sci, Res Ctr Neurosurg & Funct Nerves, Tehran, Iran

来源：

IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH | 2022年 / 21卷 / 01期

关键词：

Acute Respiratory Distress Syndrome (ARDS); Coronavirus Disease; Clinical Management; SARS-COV-2; Treatment Guidelines;

D O I：

10.5812/ijpr.123947

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

More than a year after the onset of the coronavirus disease pandemic in 2019, the disease remains a major global health issue. During this time, health organizations worldwide have tried to provide integrated treatment guidelines to control coronavirus disease 2019 (COVID-19) at different levels. However, due to the novel nature of the disease and the emergence of new variants, medical teams' updating medical information and drug prescribing guidelines should be given special attention. This version is an updated instruction of the National Research Institute of Tuberculosis and Lung Disease (NRITLD) in collaboration with a group of specialists from Masih Daneshvari Hospital in Tehran, Iran, which is provided to update the information of caring clinicians for the treatment and care of COVID-19 hospitalized patients.

引用

页数：8

共 51 条

[51] Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China [J].

Zhang, J. ;

Wang, X. ;

Jia, X. ;

Li, J. ;

Hu, K. ;

Chen, G. ;

Wei, J. ;

Gong, Z. ;

Zhou, C. ;

Yu, H. ;

Yu, M. ;

Lei, H. ;

Cheng, F. ;

Zhang, B. ;

Xu, Y. ;

Wang, G. ;

Dong, W. .

CLINICAL MICROBIOLOGY AND INFECTION, 2020, 26 (06) :767-772

← 1 2 3 4 5 6 →